Zynteglo Disease Interactions
There are 3 disease interactions with Zynteglo (betibeglogene autotemcel).
Betibeglogene (applies to Zynteglo) HIV
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: HIV Infection
Betibeglogene has not been studied in patients with HIV. A negative serology test for HIV is necessary before the collection of cells, to ensure acceptance of apheresis material for betibeglogene manufacturing. Material from patients with a positive HIV test, will not be accepted for manufacturing.
Betibeglogene (applies to Zynteglo) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Betibeglogene has not been studied in patients with hepatic impairment. Patients should be assessed for hepatic impairment to ensure that hematopoietic stem cell (HSC) transplantation is appropriate. Additionally, screening for hepatitis B and C should be performed before cell collection, to ensure acceptance of apheresis material for betibeglogene manufacturing.
Betibeglogene (applies to Zynteglo) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Betibeglogene has not been studied in patients with renal impairment. Patients should be assessed for renal impairment, to ensure that hematopoietic stem cell (HSC) transplantation is appropriate.
Switch to professional interaction data
Zynteglo drug interactions
There are 44 drug interactions with Zynteglo (betibeglogene autotemcel).
Report options
More about Zynteglo (betibeglogene autotemcel)
- Zynteglo consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Casgevy
Casgevy (exagamglogene autotemcel) is a gene therapy that is given as a one-time intravenous ...
Luspatercept
Luspatercept (brand name Reblozyl) is used to treat anemia (low red blood cells) in certain ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.